Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- Author
- SALLOWAY, Stephen1 ; SPERLING, Reisa2 ; REICHERT, Marcel11 ; KETTER, Nzeera11 ; NEJADNIK, Bijan11 ; GUENZLER, Volkmar11 ; MILOSLAVSKY, Maja11 ; WANG, Daniel11 ; YUAN LU11 ; LULL, Julia12 ; TUDOR, Iulia Cristina11 ; ENCHI LIU11 ; FOX, Nick C3 ; GRUNDMAN, Michael13 ; YUEN, Eric11 ; BLACK, Ronald14 ; BRASHEAR, H. Robert11 ; BLENNOW, Kaj4 ; KLUNK, William5 ; RASKIND, Murray6 ; SABBAGH, Marwan7 ; HONIG, Lawrence S8 ; PORSTEINSSON, Anton P10 ; FERRIS, Steven9
[1] Butler Hospital, Providence, RI, United States
[2] Brigham and Women's Hospital, Boston, United States
[3] University College London, Institute of Neurology, London, United Kingdom
[4] University of Göteborg, Sahlgrenska University Hospital, Mölndal, Sweden
[5] University of Pittsburgh, Pittsburgh, United States
[6] Veterans Affairs Medical Center, Seattle, United States
[7] Cleo Roberts Center for Clinical Research/Sun Health Research Institute, Sun City, AZ, United States
[8] Columbia University, United States
[9] New York University Langone Medical Center, New York, United States
[10] University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
[11] Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA, United States
[12] Janssen Research and Development, Titusville, NJ, United States
[13] Global R&D Partners and the University of California, San Diego, San Diego, United States
[14] Pfizer, Collegeville, PA, United States
Bapineuzumab 301 and 302 Clinical Trial Investigators - Source
The New England journal of medicine. 2014, Vol 370, Num 4, pp 322-333, 12 p ; ref : 28 ref
- CODEN
- NEJMAG
- ISSN
- 0028-4793
- Scientific domain
- General medicine general surgery
- Publisher
- Massachusetts Medical Society, Waltham, MA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Bapineuzumab Chimiothérapie Démence d'Alzheimer Efficacité traitement Essai clinique phase III Immunomodulateur Médecine Anticorps monoclonal Maladie dégénérative Pathologie de l'encéphale Pathologie du système nerveux central Pathologie du système nerveux Traitement
- Keyword (en)
- Bapineuzumab Chemotherapy Alzheimer disease Treatment efficiency Phase III trial Immunomodulator Medicine Monoclonal antibody Degenerative disease Cerebral disorder Central nervous system disease Nervous system diseases Treatment
- Keyword (es)
- Bapineuzumab Quimioterapia Demencia Alzheimer Eficacia tratamiento Ensayo clínico fase III Inmunomodulador Medicina Anticuerpo monoclonal Enfermedad degenerativa Encéfalo patología Sistema nervosio central patología Sistema nervioso patología Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B18 Psychopathology. Psychiatry / 002B18C Adult and adolescent clinical studies / 002B18C13 Organic mental disorders. Neuropsychology
- Francis
- 770 Psychology. Psychoanalysis. Psychiatry / 770-D Psychopathology. Psychiatry / 770-D03 Adult and adolescent clinical studies / 770-D03M Organic mental disorders. Neuropsychology
- Discipline
- Neurology Psychopathology. Psychiatry. Clinical psychology
- Origin
- Inist-CNRS
- Database
- FRANCIS ; PASCAL
- INIST identifier
- 28075688
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1056/NEJMoa1304839 
https://dx.doi.org/10.1056/NEJMoa1304839
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1304839\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"370\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"322\";s:8:\"\u0000*\u0000epage\";s:3:\"333\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"SALLOWAY\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Stephen\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"SPERLING, Reisa\";i:1;s:16:\"REICHERT, Marcel\";i:2;s:14:\"KETTER, Nzeera\";i:3;s:15:\"NEJADNIK, Bijan\";i:4;s:17:\"GUENZLER, Volkmar\";i:5;s:17:\"MILOSLAVSKY, Maja\";i:6;s:12:\"WANG, Daniel\";i:7;s:7:\"YUAN LU\";i:8;s:11:\"LULL, Julia\";i:9;s:21:\"TUDOR, Iulia Cristina\";i:10;s:9:\"ENCHI LIU\";i:11;s:11:\"FOX, Nick C\";i:12;s:17:\"GRUNDMAN, Michael\";i:13;s:10:\"YUEN, Eric\";i:14;s:13:\"BLACK, Ronald\";i:15;s:19:\"BRASHEAR, H. Robert\";i:16;s:12:\"BLENNOW, Kaj\";i:17;s:14:\"KLUNK, William\";i:18;s:15:\"RASKIND, Murray\";i:19;s:15:\"SABBAGH, Marwan\";i:20;s:17:\"HONIG, Lawrence S\";i:21;s:21:\"PORSTEINSSON, Anton P\";i:22;s:14:\"FERRIS, Steven\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1304839\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"370\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"322\";s:8:\"\u0000*\u0000epage\";s:3:\"333\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"SALLOWAY\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Stephen\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"SPERLING, Reisa\";i:1;s:16:\"REICHERT, Marcel\";i:2;s:14:\"KETTER, Nzeera\";i:3;s:15:\"NEJADNIK, Bijan\";i:4;s:17:\"GUENZLER, Volkmar\";i:5;s:17:\"MILOSLAVSKY, Maja\";i:6;s:12:\"WANG, Daniel\";i:7;s:7:\"YUAN LU\";i:8;s:11:\"LULL, Julia\";i:9;s:21:\"TUDOR, Iulia Cristina\";i:10;s:9:\"ENCHI LIU\";i:11;s:11:\"FOX, Nick C\";i:12;s:17:\"GRUNDMAN, Michael\";i:13;s:10:\"YUEN, Eric\";i:14;s:13:\"BLACK, Ronald\";i:15;s:19:\"BRASHEAR, H. Robert\";i:16;s:12:\"BLENNOW, Kaj\";i:17;s:14:\"KLUNK, William\";i:18;s:15:\"RASKIND, Murray\";i:19;s:15:\"SABBAGH, Marwan\";i:20;s:17:\"HONIG, Lawrence S\";i:21;s:21:\"PORSTEINSSON, Anton P\";i:22;s:14:\"FERRIS, Steven\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1304839\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1304839\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"370\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"322\";s:8:\"\u0000*\u0000epage\";s:3:\"333\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"SALLOWAY\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Stephen\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"SPERLING, Reisa\";i:1;s:16:\"REICHERT, Marcel\";i:2;s:14:\"KETTER, Nzeera\";i:3;s:15:\"NEJADNIK, Bijan\";i:4;s:17:\"GUENZLER, Volkmar\";i:5;s:17:\"MILOSLAVSKY, Maja\";i:6;s:12:\"WANG, Daniel\";i:7;s:7:\"YUAN LU\";i:8;s:11:\"LULL, Julia\";i:9;s:21:\"TUDOR, Iulia Cristina\";i:10;s:9:\"ENCHI LIU\";i:11;s:11:\"FOX, Nick C\";i:12;s:17:\"GRUNDMAN, Michael\";i:13;s:10:\"YUEN, Eric\";i:14;s:13:\"BLACK, Ronald\";i:15;s:19:\"BRASHEAR, H. Robert\";i:16;s:12:\"BLENNOW, Kaj\";i:17;s:14:\"KLUNK, William\";i:18;s:15:\"RASKIND, Murray\";i:19;s:15:\"SABBAGH, Marwan\";i:20;s:17:\"HONIG, Lawrence S\";i:21;s:21:\"PORSTEINSSON, Anton P\";i:22;s:14:\"FERRIS, Steven\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1304839\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"370\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"322\";s:8:\"\u0000*\u0000epage\";s:3:\"333\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"SALLOWAY\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Stephen\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"SPERLING, Reisa\";i:1;s:16:\"REICHERT, Marcel\";i:2;s:14:\"KETTER, Nzeera\";i:3;s:15:\"NEJADNIK, Bijan\";i:4;s:17:\"GUENZLER, Volkmar\";i:5;s:17:\"MILOSLAVSKY, Maja\";i:6;s:12:\"WANG, Daniel\";i:7;s:7:\"YUAN LU\";i:8;s:11:\"LULL, Julia\";i:9;s:21:\"TUDOR, Iulia Cristina\";i:10;s:9:\"ENCHI LIU\";i:11;s:11:\"FOX, Nick C\";i:12;s:17:\"GRUNDMAN, Michael\";i:13;s:10:\"YUEN, Eric\";i:14;s:13:\"BLACK, Ronald\";i:15;s:19:\"BRASHEAR, H. Robert\";i:16;s:12:\"BLENNOW, Kaj\";i:17;s:14:\"KLUNK, William\";i:18;s:15:\"RASKIND, Murray\";i:19;s:15:\"SABBAGH, Marwan\";i:20;s:17:\"HONIG, Lawrence S\";i:21;s:21:\"PORSTEINSSON, Anton P\";i:22;s:14:\"FERRIS, Steven\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1056\/NEJMoa1304839\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:9:\"\u0000*\u0000jtitle\";s:35:\"The New England journal of medicine\";s:9:\"\u0000*\u0000stitle\";s:15:\"N. Engl. j. med\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:3:\"370\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"322\";s:8:\"\u0000*\u0000epage\";s:3:\"333\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-4793\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"SALLOWAY\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Stephen\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:23:{i:0;s:15:\"SPERLING, Reisa\";i:1;s:16:\"REICHERT, Marcel\";i:2;s:14:\"KETTER, Nzeera\";i:3;s:15:\"NEJADNIK, Bijan\";i:4;s:17:\"GUENZLER, Volkmar\";i:5;s:17:\"MILOSLAVSKY, Maja\";i:6;s:12:\"WANG, Daniel\";i:7;s:7:\"YUAN LU\";i:8;s:11:\"LULL, Julia\";i:9;s:21:\"TUDOR, Iulia Cristina\";i:10;s:9:\"ENCHI LIU\";i:11;s:11:\"FOX, Nick C\";i:12;s:17:\"GRUNDMAN, Michael\";i:13;s:10:\"YUEN, Eric\";i:14;s:13:\"BLACK, Ronald\";i:15;s:19:\"BRASHEAR, H. Robert\";i:16;s:12:\"BLENNOW, Kaj\";i:17;s:14:\"KLUNK, William\";i:18;s:15:\"RASKIND, Murray\";i:19;s:15:\"SABBAGH, Marwan\";i:20;s:17:\"HONIG, Lawrence S\";i:21;s:21:\"PORSTEINSSON, Anton P\";i:22;s:14:\"FERRIS, Steven\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEJMAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:74:\"Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease\";s:8:\"\u0000*\u0000place\";s:11:\"Waltham, MA\";s:6:\"\u0000*\u0000pub\";s:29:\"Massachusetts Medical Society\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
